THALASSEMIAS

Feature

Managing Atrial Fibrillation in Patients With Beta Thalassemia Major

By

Patients with beta thalassemia major may be at higher risk for atrial fibrillation, creating a need for attentive clinical management.

Latest News

New Iron Chelator May Improve Cardiac Function in Patients With Beta Thalassemia

By

A new oral iron chelator, deferasirox, may confer long-term benefits to patients with beta thalassemia major.

A Novel Health-Related Quality of Life Assessment Tool for Nontransfusion-Dependent Beta Thalassemia

By

Modern tools for measuring health-related quality of life may not capture symptoms unique to patients with nontransfusion-dependent thalassemia.

Treatment Success With HLA-Matched Donor Grafts for Beta Thalassemia From Relatives and Nonrelatives

By

Researchers analyzed 1110 patients who had received transplanted grafts from HLA-matched and mismatched relatives and unrelated donors.

Allogeneic Hematopoietic Cell Transplantation for Sickle Cell Disease and Thalassemia

By

Allogeneic hematopoietic cell transplantation was tolerated well by pediatric patients with sickle cell disease and transfusion-dependent thalassemia.

Reduced Need for Red Blood Cell Transfusions in Patients Treated With Luspatercept for Beta-Thalassemia

By

The drug's ability to boost late-stage erythropoiesis makes it a potential treatment option for patients with beta-thalassemia.

Denosumab Promising for Transfusion Dependent Thalassemia-Induced Osteoporosis Treatment

Denosumab may be beneficial for managing transfusion-dependent thalassemia-induced osteoporosis.

Peripheral Blood: An Alternative Source of Stem Cells in Thalassemia

By

Accessing peripheral blood as a graft source is easier and less invasive than accessing bone marrow.

Serum Ferritin May Unreliably Predict Iron Overload in Patients with Thalassemia Major

By

Iron overload that persists after HSCT can cause long-term organ damage.

Hematopoietic Stem Cell Transplant Examined for Inherited Blood Disorder

The researchers found that in transplanted patients, the 30-year overall survival (OS) was 82.6±2.7% and thalassemia-free survival (TFS) was 77.8±2.9% compared with OS of 85.3±2.7% in CT patients (P=NS).

SIGN UP FOR FREE E-NEWSLETTERS